91精品

Original Articles

1. Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Gerburg MW, Bell EL, Shim HS, Lamia KA, Rameh LE, Bellinger G, Sasaki AT, Asars JM, Yuan X, Bullock A, DeNicola GM, Song J. Brown V, Signoretti S, and Cantley LC. Depletion of a Putatively Druggable Class of Phosphatidylinositol Kinases Inhibits Growth of p53 Null Tumors. Cell. In Press.
2. Choueiri TK, Fay AP, Gagnon R, Lin Y, Bahamon B, Brown V, Rosenberg JE, Hutson TE, Baker-Neblett KL, Carpenter C, Liu Y, Pandite L, Signoretti S. The role of aberrant VHL/HIF/VEGF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma. Clin Cancer Res. In Press.
3. Wang G, Lunardi A, Zhang J, Chen Z, Ala U, Webster KA, Tay Y, Gonzalez- Billalabeitia E, Egia A, Shaffer DR, Carver B, Liu XS, Taulli R, Kuo WP, Nardella C, Signoretti S, Cordon-Cardo C, Gerald WL & Pandolfi PP. Lrf/Pokemon suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion. Nat Genet. In Press
4. Lunardi A, Ala U, Epping MT, Salmena L, Clohessy JG, Webster KA, Wang G, Mazzucchelli R, Bianconi M, Stack EC, Lis R, Patnaik A, Cantley LC, Bubley G, Cordon-Cardo C, Gerald WL, Montironi R, Signoretti S, Loda M, Nardella C, Pandolfi PP. Identification of new molecular genetics determinants, mechanisms and therapies for prostate cancer through Co- Clinical screenings. Nat Genet. In Press.
33. Cho DC, Cohen MB, Panka DJ, Collins M, Ghebremichael M, Atkins MB, Signoretti S, Mier JW. The Efficacy of the Novel Dual PI3-Kinase/mTOR Inhibitor NVP-BEZ235 Compared to Rapamycin in Renal Cell Carcinoma. Clin Cancer Res. 2010;16(14):3628-38.
34. Lee SH, Poulogiannis G, Pyne S, Jia S, Zou L, Signoretti S, Loda M, Cantley LC, and Roberts TM. A constitutively activated form of the p110β isoform of PI3-kinase induces prostatic intraepithelial neoplasia in mice. Proc Natl Acad Sci (U S A). 2010;107(24):11002-7.
35. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX (CAIX) and pathologic features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving VEGF-targeted therapy. BJU Int. 2010;106(6):772-8.
36. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, Donovan J, Barretina J, Boehm JS, Dobson J, Urashima M, McHenry K, Pinchback R, Ligon AH, Cho J, Haery L, Greulich H, Reich M, Winckler W, Weir BA, Tanaka K, Chiang DY, Bass AJ, Loo A, Hoffman C, Prensner J, Liefeld T, Yecies D, SignorettiS, Maher E, Kaye FJ, Sasaki H, Tepper JE, Fletcher JA, Baselga J, Tsao M, Rubin MA, Janne PA, Daly MJ, Nucera C, Levine RL, Ebert BL, Gabriel S, Rustgi AK, Antonescu CR, Ladanyi M, Letai A, Garraway LA, Loda M, Beer DG, True LD, Okamoto A, Pomeroy SL, Singer S, Lander ES, Getz G, Golub TR, Sellers WR, Meyerson M. The landscape of copy number alterations across multiple human cancers. Nature. 2010;463:899-905.
44. Hulick P, Zimmer M, Margulis V, Skates S, Hamel M, Dahl M. D, Michaelson D, Liebermann T, Signoretti S, Carney W, Wood C, Iliopoulos O. Blood Levels of Carbonic Anhydrase 9 Correlate with Clear Cell Renal Cell Carcinoma Activity. Clin Proteom. 2009; 5:37-45.
89. Sgnoretti S, Annessi G. Are histopathological attributes of nevi and melanomas on volar skin related to skin markings? Dermatopathology: practical and conceptual. 1998;4:311-313.

Review Articles & Editorials

1. Ittmann M, Huang J, Radaelli E, Martin P, Signoretti S, Sullivan R, Simons BW, Ward JM, Robinson BD, Chu GC, Loda M, Thomas G, Borowsky A and Cardiff RD. Animal models of human prostate cancer: The Consensus Report of the New York Meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. Cancer Res. 2013;73(9):2718-2736.
2. Choueiri TK, Pomerantz MM, Signoretti S. RCC genetics: one step closer to a new classification of the disease. Lancet Oncol. 2013;14:105-7.
3. Atkins MB, Bukowski RM, Escudier BJ, Figlin RA, Hudes GH, Kaelin WG Jr, Linehan WM, McDermott DF, Mier JW, Pedrosa I, Rini BI, Signoretti S, Sosman JA, The BT, Wood CG, Zurita, AJ and King L. Innovations and Challenges in Renal Cancer: Summary Statement From the Third Cambridge Conference. Cancer. 2009;115(10 Suppl):2247-51.
4. Atkins MB, Choueiri TK, Cho D, Regan M, Signoretti S. Treatment Selection for Patients With Metastatic Renal Cell Carcinoma. Cancer. 2009;115(10 Suppl):2327-33.
5. Di Napoli A and Signoretti S. Tissue Biomarkers in Renal Cell Carcinoma: Issues and Solutions. Cancer. 2009;115(10 Suppl):2290-7.
6. Signoretti S. Tissue-Based Research in the Era of ‘Personalized Medicine’: Biomarkers, Microarrays, and Beyond. Kidney Cancer Journal. 2008;235-9.
7. Signoretti S, Bratslavsky G, Waldman FM, Reuter VE, Haaga J, Merino M, Thomas GV, Pins MR, Libermann T, Gillespie J, Tomaszewski JE, Compton CC, Hruszkewycz A, Linehan WM, Atkins MB. Tissue-Based Research In Kidney Cancer: Current Challenges And Future Directions. Clin Cancer Res. 2008;14(12):3699-705.
8. Signoretti S, Regan M, Atkins MB. Carbonic Anhydrase IX (CAIX) as a predictive biomarker of response to kidney cancer therapy. BJU Int. 2008; 101 Suppl 4:31-5.
9. Grisanzio C and Signoretti S. p63 in prostate biology and pathology. J Cell Biochem. 2008; 103(5):1354-68.
10. Signoretti S and Loda M. Prostate stem cells: from development to cancer. Semin Cancer Biol. 2007; 17(3):219-24.
11. Cho D, Signoretti S, Regan M, Mier JW, Atkins MB. The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer. Clin Cancer Res. 2007;13(2 Pt 2):758s-763s
12. Signoretti S and Loda M. Defining stem cells in the prostate epithelium. Cell Cycle. 2006; 5:138-41.
13. Signoretti S, Loda M. Estrogen receptor beta in prostate cancer: brake pedal or accelerator? Am J Pathol 2001;159:13-6.

Chapters In Books

1. Signoretti S, Choueiri TK, Kaelin WG. Molecular abnormalities in Kidney Cancer. In “Mendelsohn, The Molecular Basis of Cancer”. Edited by John Mendelsohn. 4th Edition. In Press.
2. Bahamon B and Signoretti S. Tissue Biomarkers in Renal Cell Carcinoma: Intermediate Endpoints in the Selection of Targeted Agents for RCC. Edited by Kimryn Rathmell, Brian Rini and Robert A. Figlin. In Press.
3. Grisanzio C and Signoretti S. Adult Prostate Epithelium Renewal, Stem Cells and Cancer. In “Stem Cells and Cancer”. Edited by Rebecca G. Bagley and Beverly A. Teicher. 2009.
4. Kamino H, Signoretti S, Weedon D. Site specific nevi. In “WHO classification of tumors: Pathology and Genetics of Skin Tumors”. Edited by LeBoit PE, Burg G, Weedon D, Sarasin A.